BioMarin acquires Lead Therapeutics for rare cancer drug candidate
This article was originally published in Scrip
Executive Summary
BioMarin Pharmaceutical is to acquire the privately held US firm Lead Therapeutics for $18 million up front in a stock purchase agreement, its second acquisition of a biotech company with a single orphan product in recent months.